|
||||||||||||||||||||||
|
|
Basic Trial Information
Summary To estimate the efficacy of Gemcitabine monotherapy compared to UFT as the post operative adjuvant chemotherapy for completely resected non-small cell lung cancer. Eligibility Criteria Inclusion Criteria: 1. completely resected non small cell lung cancer 2. no prior anti cancer treatment for thoracic malignancy exept for this operation 3. pathological stage IB, II, and stage IIIA with only one station of n2 disease 4. PS 0-1 5. age 20-75 6. adequate organ function for chemotherapy 7. written informed consent Exclusion Criteria: 1. small cell lung cancer or low grade malignancy of lung cancer 2. incomplete resection 3. apparent interstitial pneumonitis at chest rentogenogram 4. inadequate condition for chemotherapy Trial Lead Organizations/Sponsors West Japan Thoracic Oncology Group
Trial Sites
Link to the current ClinicalTrials.gov record. Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov. Back to Top |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |